USPTO 2015–2025 USPTO PatentsView US Corporation

NeoDiagnostix, Inc.

USPTO PatentsView assignee record - 5 granted patents across 5 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

RSS updates for this company

The verdict

According to USPTO PatentsView, Neodiagnostix ranks #49,014 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 5 technology areas.

#49,014
of 49,997 US assignees by volume
30th percentile
by Innovation Score (29.1/100)
26.4
avg claims per patent
-33%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R49014 · US Corporation #49,014 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-MICRO 5 grants
  • BOTTOM-DECILE #49,014/49,997
  • PHOTO-FINISH Near-Miss Management
  • CPC-NARROW C12Q · 5 areas
  • INNOV-THIN 29.1/100
  • CLAIMS-DENSE 26.4 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DOWN -33% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Near-Miss Management LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Neodiagnostix

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Neodiagnostix's Innovation Score is 29.1/100 (30th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Neodiagnostix's grants concentrate

NeoDiagnostix, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2015 (2 grants) versus a trough of 1 in 2017. By volume, Neodiagnostix sits between Near-Miss Management LLC and Neosinus Health Inc..

Who files at NeoDiagnostix's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows NeoDiagnostix holds 5 patents at rank #49,133, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near NeoDiagnostix

By rank, the assignees closest to #49,133 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in NeoDiagnostix's primary technology class.

Neodiagnostix's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 30th percentile higher than 30% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 201520172021 2
USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
NeoDiagnostix, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 2 40.0%
2017 1 20.0%
2021 2 40.0%

Where it ranks

Overall rank by patents

#49,014

of 49,997 tracked assignees

Innovation Score

29.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

NeoDiagnostix, Inc.'s patent record in context - here's where to go next.

  • NeoDiagnostix, Inc.'s lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 100% of its portfolio - see every assignee active in that class. Explore C12Q
  • Ranked #49,014 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare NeoDiagnostix, Inc. against Near-Miss Management LLC, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 29.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.